Methylglyoxal induces p53 activation and inhibits mTORC1 in human umbilical vein endothelial cells
Abstract Methylglyoxal (MGO), a precursor of advanced glycation end products (AGEs), is regarded as a pivotal mediator of vascular damage in patients with diabetes. We have previously reported that MGO induces transcriptional changes compatible with p53 activation in cultured human endothelial cells...
Guardado en:
Autores principales: | Xinmiao Zhang, Angelica Rodriguez-Niño, Diego O. Pastene, Prama Pallavi, Jacob van den Born, Stephan J. L. Bakker, Bernhard K. Krämer, Benito A. Yard |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/6ec653575d044273a6fd2d3553d72164 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
mTORC1 and mTORC2 regulate skin morphogenesis and epidermal barrier formation
por: Xiaolei Ding, et al.
Publicado: (2016) -
Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2.
por: Morris E Feldman, et al.
Publicado: (2009) -
Crosstalks between mTORC1 and mTORC2 variagate cytokine signaling to control NK maturation and effector function
por: Fangjie Wang, et al.
Publicado: (2018) -
Differential controls of MAIT cell effector polarization by mTORC1/mTORC2 via integrating cytokine and costimulatory signals
por: Huishan Tao, et al.
Publicado: (2021) -
Gut stem cell aging is driven by mTORC1 via a p38 MAPK-p53 pathway
por: Dan He, et al.
Publicado: (2020)